The role of LDH serum levels in predicting global outcome in HCC patients treated with sorafenib: Implications for clinical management

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Faloppi, Luca ^a   Scartozzi, Mario ^a   Bianconi, Maristella ^a   Svegliati Baroni, Gianluca ^a   Toniutto, Pierluigi ^b   Giampieri, Riccardo ^a   Del Prete, Michela ^a   De Minicis, Samuele ^a   Bitetto, Davide ^b   Loretelli, Cristian ^c   D'Anzeo, Marco ^a   Benedetti, Antonio ^a   Cascinu, Stefano ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^b UNIVERSITY OF UDINE   (Italy)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Angiogenesis; Hepatocellular carcinoma; Lactate dehydrogenase; Sorafenib

Indexed keywords

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; DISEASE MANAGEMENT; FEMALE; HUMANS; L-LACTATE DEHYDROGENASE; LIVER NEOPLASMS; MALE; MIDDLE AGED; NIACINAMIDE; PHENYLUREA COMPOUNDS; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84894320606     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-110     Document Type: Article

References (24)

1. Faloppi L, Scartozzi M, Maccaroni E, et al. Evolving strategies for the treatment of hepatocellular carcinoma: from clinical-guided to molecularly-tailored therapeutic options. Cancer Treat Rev 2011, 37(3):169-177. 10.1016/j.ctrv.2010.08.001, 20800360.
2. Kane RC, Farrell AT, Madabushi R, et al. Sorafenib for the treatment of unresectable hepatocellular carcinoma. Oncologist 2009, 14(1):95-100. 10.1634/theoncologist.2008-0185, 19144678.
3. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in Advanced Hepatocellular Carcinoma. N Engl J Med 2008, 359:378-390. 10.1056/NEJMoa0708857, 18650514.
4. Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009, 10(1):25-34. 10.1016/S1470-2045(08)70285-7, 19095497.
5. Llovet JM, Peña CE, Lathia CD, et al. Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma. Clin Cancer Res 2012, 18(8):2290-2300. 10.1158/1078-0432.CCR-11-2175, 22374331.
6. Holbrook JJ, Liljas A, Steindel SJ. Lactate Dehydrogenase. The Enzymes, vol. XI, part A 1975, 191-192. New York: Academic Press, Boyer PD, 3.
7. Markert CL. Lactate dehydrogenase isozymes: dissociation and recombination of subunits. Science 1963, 140:1329-1330. 10.1126/science.140.3573.1329, 17802174.
8. Semenza G. Signal transduction to hypoxia-inducible factor 1. Biochem Pharmacol 2002, 64:993-998. 10.1016/S0006-2952(02)01168-1, 12213597.
9. Semenza GL. HIF-1: mediator of physiological and pathophysiological responses to hypoxia. J Appl Physiol 2000, 88:1474-1480.
10. Maxwell PH, Dachs GU, Gleadle JM, et al. Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc Natl Acad Sci USA 1997, 94:8104-8109. 10.1073/pnas.94.15.8104, 21564, 9223322.
11. Semenza GL. Regulation of mammalian O2 homeostasis by hypoxia-inducible factor 1. Annu Rev Cell Dev Biol 1999, 15:551-578. 10.1146/annurev.cellbio.15.1.551, 10611972.
12. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010, 30(1):52-60. 10.1055/s-0030-1247132, 20175033.
13. Abou-Alfa GK. Sorafenib use in hepatocellular carcinoma: More questions than answers. Hepatology 2014, doi: 10.1002/hep.27044. [Epub ahead of print].
14. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008, 359(4):378-390. 10.1056/NEJMoa0708857, 18650514.
15. Yau T, Chan P, Ng KK, et al. Phase 2 open-label study of single-agent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis B-endemic Asian population: presence of lung metastasis predicts poor response. Cancer 2009, 115(2):428-436. 10.1002/cncr.24029, 19107763.
16. Scartozzi M, Faloppi L, Bianconi M, et al. The role of LDH serum levels in predicting global outcome in HCC patients undergoing TACE: implications for clinical management. PLoS One 2012, 7(3):e32653. 10.1371/journal.pone.0032653, 3312882, 22461886.
17. Kohles N, Nagel D, Jungst D, Durner J, Stieber P, et al. (2012) Prognostic relevance of oncological serum biomarkers in liver cancer patients undergoing chemoembolization therapy. Tumour Biol 2011, 33(1):33-40.
18. Scartozzi M, Giampieri R, Maccaroni E, et al. Pre-treatment lactate dehydrogenase levels as predictor of efficacy of first-line bevacizumab-based therapy in metastatic colorectal cancer patients. Br J Cancer 2012, 106(5):799-804. 10.1038/bjc.2012.17, 3305976, 22315053.
19. Koukourakis MI, Giatromanolaki A, Sivridis E, et al. Prognostic and predictive role of lactate dehydrogenase 5 expression in colorectal cancer patients treated with PTK787/ZK 222584 (Vatalanib) Antiangiogenic Therapy. Clin Cancer Res 2011, 17(14):4892-4900. 10.1158/1078-0432.CCR-10-2918, 3145151, 21632858.
20. Wu XZ, Ma F, Wang XL. Serological diagnostic factors for liver metastasis in patients with colorectal cancer. World J Gastroenterol 2010, 16(32):4084-4088. 10.3748/wjg.v16.i32.4084, 2928464, 20731024.
21. Kolev Y, Uetake H, Takagi Y, Sugihara K. Lactate dehydrogenase-5 (LDH-5) expression in human gastric cancer: association with hypoxia-inducible factor (HIF-1alpha) pathway, angiogenic factors production and poor prognosis. Ann Surg Oncol 2008, 15(8):2336-2344. Epub 2008 Jun 3, 10.1245/s10434-008-9955-5, 18521687.
22. Van Cutsem E, Bajetta E, Valle J, Köhne CH, Hecht JR, et al. Randomized, placebo-controlled, phase III study of oxaliplatin, fluorouracil, and leucovorin with or without PTK787/ZK 222584 in patients with previously treated metastatic colorectal adenocarcinoma. J Clin Oncol 2011, 29(15):2004-2010. 10.1200/JCO.2010.29.5436, 21464401.
23. Hecht JR, Trarbach T, Hainsworth JD, et al. Randomized, placebo-controlled, Phase III Study of first-line Oxaliplatin-Based Chemotherapy Plus PTK787/ZK222584, an oral vascular endothelial growth factor receptor inhibitor, in patients with metastatic colorectal Adenocarcinoma. J Clin Oncol. 2011, 29(15):1997-2003. Epub 2011 Apr 4, 10.1200/JCO.2010.29.4496, 21464406.
24. Fiume L, Vettraino M, Manerba M, et al. Inhibition of lactic dehydrogenase as a way to increase the anti-proliferative effect of multi-targeted kinase inhibitors. Pharmacol Res 2011, 63(4):328-334. 10.1016/j.phrs.2010.12.005, 21168502.